Even though the PD-L1 expression of tumor cell has been identified as a predictive biomarker for response of immunotherapy in both newly diagnosed or previously treated NSCLC (3, 4, 11), the relationship between the PD-L1 expression and the therapeutic effects of nivolumab is still unclear. The gene discussed is CD274; the disease is neoplasm.